Top

Published in:

01-11-2017 | Pictorial essay

Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer

Authors: Jooae Choe, Marta Braschi-Amirfarzan, Sree Harsha Tirumani, Atul B. Shinagare, Kyung Won Kim, Nikhil H. Ramaiya, Katherine M. Krajewski

Published in: Abdominal Radiology | Issue 11/2017

Abstract

Urothelial bladder cancer is a common malignancy requiring a multidisciplinary approach to treatment. Significant recent advances have been made in terms of the genetic and molecular characterization of bladder cancer subtypes, and novel treatment approaches are being investigated and approved. Given the important role of imaging in the diagnosis, staging, and follow-up of this disease, it is necessary for radiologists to remain up-to-date in terms of nomenclature and standards of care. In this review, recent developments in bladder cancer characterization and treatment will be discussed, with reference to the contributions of imaging in non-muscle-invasive, muscle-invasive, and metastatic settings.

American Cancer Society. Key statistics for bladder cancer. http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-key-statistics. Accessed 23 May 2016

Davis R, Jones JS, Barocas DA, et al. (2012) Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol 188:2473–2481. doi:10.1016/j.juro.2012.09.078 CrossRefPubMed

American Cancer Society. Signs and symptoms of bladder cancer http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-signs-and-symptoms. 2016

American College of Radiology. ACR appropriateness criteria. Topic: hematuria https://acsearch.acr.org/docs/69490/Narrative/. 2014

Mariani AJ, Mariani MC, Macchioni C, et al. (1989) The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 141:350–355CrossRefPubMed

Grossfeld GD, Litwin MS, Wolf JS, et al. (2001) Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy—part I: definition, detection, prevalence, and etiology. Urology 57:599–603CrossRefPubMed

Shinagare AB, Silverman SG, Gershanik EF, et al. (2014) Evaluating hematuria: impact of guideline adherence on urologic cancer diagnosis. Am J Med 127:625–632. doi:10.1016/j.amjmed.2014.02.013 CrossRefPubMed

Black PC, Brown GA, Dinney CP (2009) The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 27:3–7. doi:10.1016/j.urolonc.2007.07.010 CrossRefPubMed

Wasco MJ, Daignault S, Zhang Y, et al. (2007) Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 70:69–74. doi:10.1016/j.urology.2007.03.033 CrossRefPubMed

10.

Moch H, Humphrey PA, Ulbright TM, Reuter V (2016) WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer

11.

Wong-You-Cheong JJ, Woodward PJ, Manning MA, Sesterhenn IA (2006) From the archives of the AFIP: neoplasms of the urinary bladder: radiologic–pathologic correlation. Radiographics 26:553–580. doi:10.1148/rg.262055172 CrossRefPubMed

12.

Burger M, Catto JW, Dalbagni G, et al. (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234–241. doi:10.1016/j.eururo.2012.07.033 CrossRefPubMed

13.

Saito W, Amanuma M, Tanaka J, Heshiki A (2000) Histopathological analysis of a bladder cancer stalk observed on MRI. Magn Reson Imaging 18:411–415CrossRefPubMed

14.

Billerey C, Chopin D, Aubriot-Lorton MH, et al. (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158:1955–1959. doi:10.1016/s0002-9440(10)64665-2 CrossRefPubMedPubMedCentral

15.

van Rhijn BW, Lurkin I, Radvanyi F, et al. (2001) The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61:1265–1268PubMed

16.

See WA (2013) Commentary on “Carboplatin based induction chemotherapy for nonorgan confined bladder cancer—a reasonable alternative for cisplatin unfit patients?” Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands: J Urol 2012;188(4):1108–1113 (Epub 2012 Aug 15). Urol Oncol 31:716–717. doi:10.1016/j.urolonc.2013.03.012

17.

Duenas M, Martinez-Fernandez M, Garcia-Escudero R, et al. (2015) PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors. Mol Carcinog 54:566–576. doi:10.1002/mc.22125 CrossRefPubMed

18.

Solomon JP, Hansel DE (2015) Morphologic and molecular characteristics of bladder cancer. Surg Pathol Clin 8:663–676. doi:10.1016/j.path.2015.07.003 CrossRefPubMed

19.

Humphrey PA, Moch H, Cubilla AL, et al. (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs—part b: prostate and bladder tumours. Eur Urol 70:106–119. doi:10.1016/j.eururo.2016.02.028 CrossRefPubMed

20.

Lindgren D, Frigyesi A, Gudjonsson S, et al. (2010) Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 70:3463–3472. doi:10.1158/0008-5472.can-09-4213 CrossRefPubMed

21.

The Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315–322. doi:10.1038/nature12965 CrossRef

22.

National Comprehensive Cancer Network. (2016) NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines) Bladder Cancer (version 2.2016)

23.

van der Heijden AG, Witjes JA (2009) Recurrence, progression, and follow-up in non–muscle-invasive bladder cancer. Eur Urol Suppl 8:556–562. doi:10.1016/j.eursup.2009.06.010 CrossRef

24.

Palou J, Rodriguez-Rubio F, Huguet J, et al. (2005) Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol 174:859–861 (discussion 861). doi:10.1097/01.ju.0000169424.79702.6d CrossRefPubMed

25.

Caoili EM, Cohan RH, Inampudi P, et al. (2005) MDCT urography of upper tract urothelial neoplasms. AJR Am J Roentgenol 184:1873–1881. doi:10.2214/ajr.184.6.01841873 CrossRefPubMed

26.

Cowan NC, Turney BW, Taylor NJ, et al. (2007) Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int 99:1363–1370. doi:10.1111/j.1464-410X.2007.06766.x CrossRefPubMed

27.

Van Der Molen AJ, Cowan NC, Mueller-Lisse UG, et al. (2008) CT urography: definition, indications and techniques. A guideline for clinical practice. Eur Radiol 18:4–17. doi:10.1007/s00330-007-0792-x CrossRef

28.

Knox MK, Cowan NC, Rivers-Bowerman MD, Turney BW (2008) Evaluation of multidetector computed tomography urography and ultrasonography for diagnosing bladder cancer. Clin Radiol 63:1317–1325. doi:10.1016/j.crad.2008.07.003 CrossRefPubMed

29.

Cohan RH, Caoili EM, Cowan NC, et al. (2009) MDCT urography: exploring a new paradigm for imaging of bladder cancer. Am J Roentgenol 192:1501–1508. doi:10.2214/AJR.09.2344 CrossRef

30.

Sadow CA, Silverman SG, O’Leary MP, Signorovitch JE (2008) Bladder cancer detection with CT urography in an Academic Medical Center. Radiology 249:195–202. doi:10.1148/radiol.2491071860 CrossRefPubMed

31.

Ma W, Kang SK, Hricak H, et al. (2009) Imaging appearance of granulomatous disease after intravesical Bacille Calmette–Guérin (BCG) treatment of bladder carcinoma. Am J Roentgenol 192:1494–1500. doi:10.2214/AJR.08.1962 CrossRef

32.

Tekes A, Kamel I, Imam K, et al. (2005) Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR Am J Roentgenol 184:121–127. doi:10.2214/ajr.184.1.01840121 CrossRefPubMed

33.

Verma S, Rajesh A, Prasad SR, et al. (2012) Urinary bladder cancer: role of MR imaging. Radiographics 32:371–387. doi:10.1148/rg.322115125 CrossRefPubMed

34.

Takeuchi M, Sasaki S, Naiki T, et al. (2013) MR imaging of urinary bladder cancer for T-staging: a review and a pictorial essay of diffusion-weighted imaging. J Magn Reson Imaging 38:1299–1309. doi:10.1002/jmri.24227 CrossRefPubMed

35.

Takeuchi M, Sasaki S, Ito M, et al. (2009) Urinary bladder cancer: diffusion-weighted MR imaging—accuracy for diagnosing T stage and estimating histologic grade. Radiology 251:112–121. doi:10.1148/radiol.2511080873 CrossRefPubMed

36.

Kim B, Semelka RC, Ascher SM, et al. (1994) Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 193:239–245. doi:10.1148/radiology.193.1.8090898 CrossRefPubMed

37.

Thoeny HC, Froehlich JM, Triantafyllou M, et al. (2014) Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging. Radiology 273:125–135. doi:10.1148/radiol.14132921 CrossRefPubMed

38.

Mir N, Sohaib SA, Collins D, Koh DM (2010) Fusion of high b-value diffusion-weighted and T2-weighted MR images improves identification of lymph nodes in the pelvis. J Med Imaging Radiat Oncol 54:358–364. doi:10.1111/j.1754-9485.2010.02182.x CrossRefPubMed

39.

Thoeny HC, Forstner R, Keyzer FD (2012) Genitourinary applications of diffusion-weighted MR imaging in the pelvis. Radiology 263:326–342. doi:10.1148/radiol.12110446 CrossRefPubMed

40.

Ganeshalingam S, Koh DM (2009) Nodal staging. Cancer Imaging 9:104–111CrossRefPubMedPubMedCentral

41.

Beyersdorff D, Zhang J, Schoder H, et al. (2008) Bladder cancer: can imaging change patient management? Curr Opin Urol 18:98–104. doi:10.1097/MOU.0b013e3282f13aac CrossRefPubMed

42.

Zhang J, Gerst S, Lefkowitz RA, Bach A (2007) Imaging of bladder cancer. Radiol Clin N Am 45:183–205. doi:10.1016/j.rcl.2006.10.005 CrossRefPubMed

43.

Rajesh A, Sokhi HK, Fung R, et al. (2011) Bladder cancer: evaluation of staging accuracy using dynamic MRI. Clin Radiol 66:1140–1145. doi:10.1016/j.crad.2011.05.019 CrossRefPubMed

44.

Swinnen G, Maes A, Pottel H, et al. (2010) FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 57:641–647. doi:10.1016/j.eururo.2009.05.014 CrossRefPubMed

45.

Paik ML, Scolieri MJ, Brown SL, et al. (2000) Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol 163:1693–1696CrossRefPubMed

46.

Bouchelouche K, Oehr P (2008) Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol 179:34–45. doi:10.1016/j.juro.2007.08.176 CrossRefPubMed

47.

Orevi M, Klein M, Mishani E, et al. (2012) 11C-acetate PET/CT in bladder urothelial carcinoma: intraindividual comparison with 11C-choline. Clin Nucl Med 37:e67–e72. doi:10.1097/RLU.0b013e31824786e7 CrossRefPubMed

48.

Ceci F, Bianchi L, Graziani T, et al. (2015) 11C-choline PET/CT and bladder cancer: lymph node metastasis assessment with pathological specimens as reference standard. Clin Nucl Med 40:e124–e128. doi:10.1097/rlu.0000000000000604 CrossRefPubMed

49.

Clark PE, Spiess PE, Agarwal N, et al. (2016) NCCN guidelines insights: bladder cancer, version 2.2016. J Natl Compr Cancer Netw 14:1213–1224CrossRef

50.

Harshman LC, Preston MA, Bellmunt J, Beard C (2015) Diagnosis of bladder carcinoma: a clinician’s perspective. Surg Pathol Clin 8:677–685. doi:10.1016/j.path.2015.07.004 CrossRefPubMed

51.

Cognetti F, Ruggeri EM, Felici A, et al. (2012) Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 23:695–700. doi:10.1093/annonc/mdr354 CrossRefPubMed

52.

Nishimura K, Fujiyama C, Nakashima K, et al. (2009) The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall. Int Urol Nephrol 41:869–875. doi:10.1007/s11255-009-9566-5 CrossRefPubMed

53.

Barentsz JO, Berger-Hartog O, Witjes JA, et al. (1998) Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207:791–797. doi:10.1148/radiology.207.3.9609906 CrossRefPubMed

54.

Schrier BP, Peters M, Barentsz JO, Witjes JA (2006) Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol 49:698–703. doi:10.1016/j.eururo.2006.01.022 CrossRefPubMed

55.

Choueiri TK, Jacobus S, Bellmunt J, et al. (2014) Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 32:1889–1894. doi:10.1200/JCO.2013.52.4785 CrossRefPubMed

56.

Dash A, Pettus JA, Herr HW, et al. (2008) A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 113:2471–2477. doi:10.1002/cncr.23848 CrossRefPubMedPubMedCentral

57.

Shinagare AB, Sadow CA, Silverman SG (2013) Surveillance of patients with bladder cancer following cystectomy: yield of CT urography. Abdom Imaging 38:1415–1421. doi:10.1007/s00261-013-0024-6 CrossRefPubMed

58.

National Institutes of Health. SEER Stat Fact Sheets: Bladder Cancer 2013. https://seer.cancer.gov/statfacts/html/urinb.html

59.

American Cancer Society (2016) Cancer treatment & survivorship facts & figures 2016–2017. Atlanta: American Cancer Society

60.

Moschini M, Karnes RJ, Sharma V, et al. (2016) Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: a 20-year single center experience. Eur J Surg Oncol 42:735–743. doi:10.1016/j.ejso.2016.02.011 CrossRefPubMed

61.

Mitra AP, Quinn DI, Dorff TB, et al. (2012) Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int 109:846–854. doi:10.1111/j.1464-410X.2011.10455.x CrossRefPubMed

62.

Sanderson KM, Cai J, Miranda G, et al. (2007) Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol 177:2088–2094. doi:10.1016/j.juro.2007.01.133 CrossRefPubMed

63.

Umbreit EC, Crispen PL, Shimko MS, et al. (2010) Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma. Cancer 116:3399–3407. doi:10.1002/cncr.25202 CrossRefPubMed

64.

Shinagare AB, Ramaiya NH, Jagannathan JP, et al. (2011) Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol 196:117–122. doi:10.2214/ajr.10.5036 CrossRefPubMed

65.

Wallmeroth A, Wagner U, Moch H, et al. (1999) Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): an autopsy study on 367 patients. Urol Int 62:69–75CrossRefPubMed

66.

von der Maase H, Sengelov L, Roberts JT, et al. (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608. doi:10.1200/jco.2005.07.757 CrossRefPubMed

67.

Rosenberg JE, Hoffman-Censits J, Powles T, et al. (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920. doi:10.1016/s0140-6736(16)00561-4 CrossRefPubMedPubMedCentral

68.

Wolchok JD, Hoos A, O’Day S, et al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420. doi:10.1158/1078-0432.ccr-09-1624 CrossRefPubMed

69.

de Velasco G, Krajewski KM, Albiges L, et al. (2016) Radiologic heterogeneity in responses to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma. Cancer Immunol Res 4:12–17. doi:10.1158/2326-6066.cir-15-0197 CrossRefPubMed

70.

Nishino M, Tirumani SH, Ramaiya NH, Hodi FS (2015) Cancer immunotherapy and immune-related response assessment: the role of radiologists in the new arena of cancer treatment. Eur J Radiol 84:1259–1268. doi:10.1016/j.ejrad.2015.03.017 CrossRefPubMedPubMedCentral

71.

Kwak JJ, Tirumani SH, Van den Abbeele AD, et al. (2015) Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics 35:424–437. doi:10.1148/rg.352140121 CrossRefPubMed

72.

Bronstein Y, Ng CS, Hwu P, Hwu WJ (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197:W992–W1000. doi:10.2214/ajr.10.6198 CrossRefPubMed

73.

Nishino M, Ramaiya NH, Awad MM, et al. (2016) PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 22:6051–6060. doi:10.1158/1078-0432.ccr-16-1320 CrossRefPubMed

74.

Balar A, Bellmunt J, O’Donnell PH, et al. (2016) Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: preliminary results from the phase 2 KEYNOTE-052 study. Ann Oncol. doi:10.1093/annonc/mdw435.25

75.

Powles T, Huddart RA, Elliott T, et al. (2017) Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor ½—positive metastatic bladder cancer. J Clin Oncol 35:48–55. doi:10.1200/JCO.2015.66.3468 CrossRefPubMed

Title: Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer
Authors: Jooae Choe
Marta Braschi-Amirfarzan
Sree Harsha Tirumani
Atul B. Shinagare
Kyung Won Kim
Nikhil H. Ramaiya
Katherine M. Krajewski
Publication date: 01-11-2017
Publisher: Springer US
Published in: Abdominal Radiology / Issue 11/2017
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-017-1195-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2017

Real-time elastography (RTE): a valuable sonography-based non-invasive method for the assessment of liver fibrosis in chronic hepatitis B

Diagnostic accuracy for neoplastic IPMN: does the contrast make the difference?

Whole-volume vs. segmental CT texture analysis of the liver to assess metachronous colorectal liver metastases

Multiparametric magnetic resonance imaging for transition zone prostate cancer: essential findings, limitations, and future directions

Benign nodules in post-Fontan livers can show imaging features considered diagnostic for hepatocellular carcinoma

Nontraumatic large bowel perforation: spectrum of etiologies and CT findings

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page